Tanja Obradovic: Clinical development includes the need to have critical focus on inclusion and diversity
Tanja Obradovic, Vice President of Oncology Scientific Affairs at
“Driving successful clinical development includes the need to have a critical focus on inclusion and diversity. Great discussion ahead at this meeting. Looking forward to input by my colleague Tinaya Gray sharing perspective from our ICON dedication to always put patients first in everything we do.”
Quoting H1’s post:
“We’d love to have you join us next week for a fireside chat all about Equity and Ethics in clinical trials as we move further into 2024 – exclusively with H1 and FirstWord Pharma!
Our panelists will walk you through where we left off with DEI in clinical trials in 2023 and what we learned from the November FDA workshop.
Explore the major roadblocks to building strategies that meet diversity requirements and get an idea of what a solid strategy should look like. Understand the full value of improving equity in trials and consider what’s been working and what needs to change.
Panelists:
– Ryan Brown, Regional Vice President, H1
– Tinaya Gray, Director, Global Head Diversity in Clinical Trials, ICON plc
– William Fitzsimmons, Pharm.D., M.S., Founder, Tutela Pharmaceuticals Inc.
Hope you can join us! Register here.”
Source: Tanja Obradovic/LinkedIn and H1/LinkedIn